The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments.
OBJECTIVE
To determine the effect of topical treatments on the conjunctiva in dry eye.


METHODS
N = 134 dry eye subjects were diagnosed using a protocol of McMonnies dry eye symptom survey score > 14, fluorescein break up time (FBUT) < 10 s and presence of rose Bengal staining. Differential diagnosis of dry eye subtypes was based on biomicroscopic signs and ocular/medical history. Superficial perilimbal bulbar conjunctival epithelial samples were collected using impression cytology. The nucleo-cytoplasmic ratio (N/C), goblet cell density (GCD) and expression of monoclonal antibodies HLA DR and CD23 were determined. The ocular surface characteristics of untreated subjects, those receiving preserved dry eye treatments and those receiving non-preserved treatments were compared with each other and with controls. Ocular surface characteristics of dry eye subtypes were also examined.


RESULTS
An increase in N/C (p = 0.011), reduction in GCD (p = 0.0001) and increase in expression of HLA DR (p = 0.0001) and CD23 (p = 0.0001) were detected in the untreated group compared to controls. No significant differences were found between the group receiving non-preserved dry eye treatments and untreated dry eye group. The group receiving preserved treatments had a reduced GCD (p = 0.0003) and increased expression of HLA DR (p = 0.0003) and CD23 (p = 0.0001) compared to the group receiving non-preserved treatments. Dry eye subtype specific differences in HLA DR and CD23 expression were noted.


CONCLUSIONS
The conjunctival inflammation and reduced goblet cell density of dry eye is exacerbated by use of preserved topical agents, and is not significantly improved by use of non-preserved artificial tear supplements alone. Therapeutic strategies for dry eye should aim to increase goblet cell density and control ocular surface inflammation.
Albietz
J M
JM
Centre for Eye Research, Queensland University of Technology, Brisbane, Australia. julie@darkoptics.com.au
Bruce
A S
AS
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002452:Cell Count; D003228:Conjunctiva / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D015352:Dry Eye Syndromes / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D004848:Epithelium / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D005260:Female; D020397:Goblet Cells / Q000187:drug effects / Q000473:pathology; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D008297:Male; D008679:Metaplasia; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000627:therapeutic use; D011310:Preservatives, Pharmaceutical / Q000008:administration & dosage* / Q000627:therapeutic use; D017455:Receptors, IgE / Q000378:metabolism
D006684:HLA-DR Antigens; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical; D017455:Receptors, IgE